Is Eli Lilly's Management Charting the Right Course?

In the following video, Motley Fool healthcare analyst David Williamson takes a look at Eli Lilly's (NYSE: LLY  )  CEO, John Lechleiter, examining both how his background as a scientist makes him an a rarity in big pharma and highlighting his rise to the top of Eli Lilly. David then tells investors why Lechleiter's background is both a strength for the company -- and a potential weakness.

Is Eli Lilly a buy or sell?
With two of its top three drugs poised to lose patent protection this year, is Eli Lilly a dividend stock headed nowhere fast? In a new premium report, The Motley Fool's senior pharmaceuticals analyst breaks down all of Lilly's moving parts, including an in-depth analysis of the company's must-know opportunities and reasons to buy and sell today. To find out more click here to claim your copy today.


Read/Post Comments (1) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 24, 2013, at 11:15 AM, DannyHaszard wrote:

    Generic Zyprexa (Olanzapine) still a cash cow.

    There is a case to be made that the drug companies like Eli Lilly,knew exactly what they were doing to off-label Zyprexa.Zyprexa made them $70 billion dollars they paid no more than $4 billion in fines and lawsuits.-Daniel Haszard Zyprexa victim advocate.

Add your comment.

DocumentId: 2327944, ~/Articles/ArticleHandler.aspx, 4/18/2014 9:53:34 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 1 day ago Sponsored by:
DOW 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASD 4,095.52 0.00 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

4/17/2014 4:00 PM
LLY $60.43 Up +0.47 +0.78%
Eli Lilly & Co. CAPS Rating: ***
JNJ $98.96 Up +0.21 +0.21%
Johnson & Johnson CAPS Rating: ****
PFE $30.25 Up +0.16 +0.53%
Pfizer CAPS Rating: ****

Advertisement